Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges

Luc Hessel,,

DOI: https://doi.org/10.1111/j.1750-2659.2009.00085.x

2009-07-01

Influenza and Other Respiratory Viruses

Abstract:An influenza pandemic will place an enormous strain on the world's vaccine production, distribution and administration systems. Following a pandemic declaration, industry's priority will be to deliver as much vaccine in as short a timeframe as possible. In respect to this challenge, manufacturers have successfully developed antigen-sparing strategies and significantly increased production capacity, with further growth planned assuming ongoing rising demand for seasonal vaccines. The combination of these factors has the potential to closer meet global needs for vaccine supply than ever before through increased availability of pandemic and pre-pandemic vaccines. The demonstration of cross-clade reactivity with H5N1 viruses makes the concept of pre-pandemic stockpiling and vaccination a reality for this subtype. Ensuring these vaccines are made available in a timely fashion to those who need them will present significant challenges. For local authorities, national governments and international organisations this means defining vaccine allocation and procurement processes as well as strengthening, and where necessary establishing, the critical health systems and infrastructure required for vaccine deployment. For vaccine producers this means addressing the technical and logistical issues associated with supply. This includes working with regulators to streamline key procedures, including generic labelling and batch release, while establishing flexibility in supply formats, including bulk and finished products, to maximise the speed of delivery. Similarly, the deployment of large quantities of vaccines in an emergency situation requires appropriate transport infrastructure and the distribution of associated medical supplies. As well as addressing these issues, specific consideration must be given to the logistics and storage aspects associated with stockpiling pre-pandemic vaccines. Finally, mutually agreed contractual arrangements between manufacturers and governments or international institutions represent the best approach toward addressing supply challenges and assisting vaccine producers meet national and international demand. To be effective, these contracts should be based on accurate forecasts, clearly defined vaccination strategies and the capabilities of public health infrastructure.

infectious diseases,virology

What problem does this paper attempt to address?

This paper aims to address the challenges faced by vaccine production, distribution, and deployment during an influenza pandemic. Specifically, the authors focus on how to provide sufficient high - quality vaccines as soon as possible to rapidly immunize global communities after a pandemic is declared. The paper discusses the progress made by manufacturers in vaccine research and development and production capacity, as well as the technical and logistical issues that need to be addressed in response to a pandemic. These issues include:

1. **Timeliness and adequacy of vaccine supply**: Through research and development efforts and cooperation with regulatory agencies, producers have developed prototype vaccines based on model influenza strains and strains with pandemic potential. These vaccines can be updated after the pandemic strain has been identified and characterized. In addition, manufacturers have adopted antigen - sparing techniques and cross - strain immunization techniques, which have significantly reduced the antigen levels required to induce a neutralizing antibody response and provided cross - reactivity against different avian influenza virus strains.

2. **Expansion of seasonal vaccine production capacity**: Since 2003, the number of distributed doses of seasonal vaccines has increased from approximately 300 million to over 400 million in 2007, and is expected to increase further significantly by 2010 if demand continues to rise.

3. **Ongoing challenges in vaccine supply, deployment, and management**: Despite significant progress in ensuring vaccine supply, the industry, governments, and international public health organizations still face obstacles that need to be addressed, such as optimizing vaccine performance, completing the development and licensing process, ensuring product stability, adequacy of storage and supply chains, and vaccine filling and packaging capacity.

4. **Success factors for ensuring vaccine availability**: In order to make vaccines accessible to the population during a pandemic, several key processes need to be completed in advance, including formulating and finalizing immunization strategies, forecasting demand, ensuring appropriate regulatory processes, strengthening public health infrastructure, and ensuring vaccine supply.

5. **Vaccine supply, deployment, and management during a pandemic**: The pandemic influenza immunization process will be very challenging, especially in situations where there is great pressure on medical services and possible disruptions due to public panic and social unrest. The paper explores how to overcome the limitations of traditional vaccine distribution and management models by improving existing infrastructure and establishing additional capacity.

In conclusion, the paper emphasizes that in influenza pandemic preparedness, coordinated efforts on multiple fronts are required, including cooperation among industry, health authorities, regulatory agencies, and international organizations, to ensure the effective supply and deployment of vaccines.